Formosa Pharmaceuticals Secures Licensing Deal with DÁVI Farmacêutica
Today, Formosa Pharmaceuticals has exciting news as it enters into an exclusive partnership with DÁVI Farmacêutica. Together, they aim to commercialize a promising treatment for patients recovering from ocular surgery. Clobetasol propionate ophthalmic suspension, known as APP13007, is a cutting-edge medicine designed to alleviate inflammation and pain.
About the Partnership and Product
Under this agreement, Formosa Pharmaceuticals has granted DÁVI exclusive rights to market APP13007 in select territories. This strategic partnership allows Formosa to leverage DÁVI's extensive experience in the ophthalmic market of Portugal, where DÁVI has earned a reputation over a century as a pivotal distributor and promoter of high-quality pharmaceutical products.
Clobetasol Propionate Ophthalmic Suspension Overview
APP13007 features clobetasol propionate, a superpotent corticosteroid that successfully addresses post-operative inflammation and pain. This formulation is derived from Formosa's proprietary APNT technology, offering a simple dosing regimen of twice daily for fourteen days. Recent surveys conducted by ophthalmic surgeons showcase the rapid effectiveness of this treatment, with approximately 80% of patients experiencing significant pain relief just four days after their procedures.
Market Potential and Impact
Portugal sees nearly 90,000 cataract surgeries annually, providing a significant opportunity for APP13007's introduction into the market. The feedback from healthcare professionals indicates a strong desire for effective treatment options that prioritize patient wellness during recovery.
Statements from Leadership
Erick Co, the President and CEO of Formosa Pharmaceuticals, remarked, "Partnering with DÁVI Farmacêutica marks our debut in a competitive EU market. We are enthusiastic about this opportunity to expand our reach into other European territories in the future. DÁVI's deep commitment to innovative ophthalmic therapies aligns perfectly with our vision for APP13007. We believe this product will provide valuable support to patients recovering from ocular surgery."
DÁVI Farmacêutica’s Business Development Manager, Rui Alves, also expressed enthusiasm: "Teaming up with Formosa enables us to present this novel treatment to our network of ophthalmologists and patients, reinforcing our dedication to their well-being. We look forward to this collaboration bringing enhanced solutions to those who need them most."
About Formosa Pharmaceuticals
Formosa Pharmaceuticals, Inc. (6838.TW) is a forward-thinking clinical stage biotechnology company dedicated to finding innovative solutions in ophthalmology and oncology. By harnessing its proprietary nanoparticle formulation technology, APNT, the company aims to improve the effectiveness of its treatments, providing high uniformity, purity, and stability in its products.
About DÁVI Farmacêutica
DÁVI Farmacêutica, a well-established company in Portugal, focuses on the distribution and promotion of exceptional branded medicines. With cooperative ties to leading global pharmaceutical firms, DÁVI is devoted to improving the health outcomes of patients by offering top-tier treatment options.
Frequently Asked Questions
What is the significance of the partnership between Formosa and DÁVI?
The partnership allows Formosa Pharmaceuticals to expand its presence in the EU market by leveraging DÁVI's established reputation and expertise in ophthalmic products.
What is APP13007?
APP13007 is a clobetasol propionate ophthalmic suspension designed to treat inflammation and pain following ocular surgery.
What technology does Formosa use to create its products?
Formosa employs its proprietary APNT technology, which enhances the bioavailability and efficacy of its formulations.
How does APP13007 impact patient recovery?
Clinical surveys have shown that APP13007 provides rapid pain relief, significantly improving patient recovery experiences after ocular surgeries.
What is DÁVI's role in this agreement?
DÁVI has been given exclusive rights to market and promote APP13007 in the Portuguese market, drawing on its extensive experience and network in the industry.
